Literature DB >> 8763433

Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema.

A P Bewley1, J S Ross, C B Bunker, R C Staughton.   

Abstract

We report a patient with the glucagonoma syndrome and octreotide-resistant necrolytic migratory erythema (NME). The NME responded on two occasions to an intravenous infusion of essential fatty acids (EFA) and amino acids (AA). A deficit of serum EFA prior to treatment was corrected following the infusion, whilst plasma AA were low before and after treatment. These findings indicate that NME, in the glucagonoma syndrome, may respond to correction of the EFA deficit, and that NME may be a disease of EFA deficiency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763433

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

Review 1.  Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.

Authors:  Wouter W de Herder; Steven W J Lamberts
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

2.  Resolution of necrolytic migratory erythema with somatostatin analogue in a patient diagnosed with pancreatic glucagonoma.

Authors:  Cristina Saavedra; Angela Lamarca; Richard A Hubner
Journal:  BMJ Case Rep       Date:  2019-08-10

3.  A case of necrolytic migratory erythema managed for 24 months with intravenous amino acid and lipid infusions.

Authors:  Jonathan F Bach; Seth A Glasser
Journal:  Can Vet J       Date:  2013-09       Impact factor: 1.008

4.  Neuroendocrine Tumors of the Pancreas.

Authors:  James M. McLoughlin; Joseph A. Kuhn; Jeffrey T. Lamont
Journal:  Curr Treat Options Gastroenterol       Date:  2004-10

5.  Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides.

Authors:  Chika Watanabe; Yusuke Seino; Hiroki Miyahira; Michiyo Yamamoto; Ayako Fukami; Nobuaki Ozaki; Yoshiko Takagishi; Jun Sato; Tsutomu Fukuwatari; Katsumi Shibata; Yutaka Oiso; Yoshiharu Murata; Yoshitaka Hayashi
Journal:  Diabetes       Date:  2012-01       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.